NVTA - Invitae Corporation
| Previous Close | 17.72 |
| Open | 17.78 |
| Bid | 17.20 x 800 |
| Ask | 17.22 x 1300 |
| Day's Range | 17.03 - 17.97 |
| 52 Week Range | 9.04 - 28.75 |
| Volume | 438,242 |
| Avg. Volume | 1,849,403 |
| Market Cap | 1.7B |
| Beta (3Y Monthly) | 2.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.29 |
| Earnings Date | Nov 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.17 |
- PR Newswire
Invitae Announces Program with BioMarin to Expand Access to Genetic Testing for Skeletal Dysplasias
Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of Discover Dysplasias™, an initiative with BioMarin Pharmaceutical to offer genetic testing at no charge to patients who show signs or symptoms of having a skeletal dysplasia, a group of rare, mostly genetic disorders that affect bones and joints and impact growth and development in children.
- Investor's Business Daily
Genetic Testing Companies Take DNA Tests To A Whole New Level
Genetic testing firms like Natera, Invitae and Fulgent are benefiting from declining costs in whole genome sequencing, a version of DNA exams that could conquer current consumer varieties.
- Simply Wall St.
Invitae (NYSE:NVTA) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
- PR Newswire
Invitae to Participate in the 31st Annual Piper Jaffray Healthcare Conference
SAN FRANCISCO , Nov. 21, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Shelly Guyer , chief financial officer of Invitae, will participate ...
- PR Newswire
Invitae Launches Invitae Discover Research Platform on Apple Watch; First Study on Platform Will Investigate Genetic Causes of Cardiovascular Disease
PHILADELPHIA, Nov. 15, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced Invitae Discover, a clinical research platform that leverages biometric data available through Apple Watch to provide better understanding of the genetic causes of disease. The first study on the platform will evaluate genetics in cardiovascular disease and was announced in conjunction with the American Heart Association's Scientific Sessions where researchers are presenting data on genetic screening in familial hypercholesterolemia.
- American City Business Journals
The Funded: Two hefty rounds lead $800M in Bay Area startup funding at midweek
The two big rounds were a $400 million round for a Chinese Tesla competitor whose U.S. operations are in Mountain View and a $100 million round for San Francisco-based food delivery unicorn DoorDash.
- Thomson Reuters StreetEvents
Edited Transcript of NVTA earnings conference call or presentation 6-Nov-19 9:30pm GMT
Q3 2019 Invitae Corp Earnings Call
- American City Business Journals
This simple acquisition shows how genetic testing is consolidating, cozying up to doctors and patients
Invitae's third acquisition in four months is indicative of consolidation in the genetic testing arena.
- PR Newswire
Invitae to Acquire Clear Genetics
SAN FRANCISCO, Nov. 11, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Clear Genetics, a leading developer of software for providing genetic services at scale. Using intuitive chatbots, Clear Genetics equips patients with actionable information throughout the genetic testing process and provides guidance for understanding test results. The acquisition will further expand Invitae's ability to scale and deliver genetic information as a part of routine medical care.
- PR Newswire
University of Vermont Health Network begins offering Genomic DNA Testing
BURLINGTON, Vt., Nov. 8, 2019 /PRNewswire/ -- The University of Vermont Health Network has begun a pilot project to offer Genomic DNA Testing to patients as part of their clinical care. The pilot program is the beginning of an effort to increase the integration of genetic disease risks into routine medical care, which holds promise for providing Vermonters with valuable information to guide their health decisions. "Our overall health and longevity are determined about 30 percent by genetics," said Debra Leonard, MD, PhD, Chair, Pathology and Laboratory Medicine.
- ETF Trends
The Unloved Biotechnology ETF Rally
Biotechnology stocks have been outperforming over the past month, but ETF investors seem disinterested and are even trimming exposure to this sector. In a weekly update on the flow of money in and out of stock funds, PiperJaffray analyst Christopher J. Raymond pointed out that investors pulled a net $99 million out of healthcare and biotech-related funds in the one-week period ended on Wednesday, Barron's reports. The latest redemptions seems surprising given the recent outperformance of the biotechnology sector.
- Zacks
Invitae (NVTA) Reports Q3 Loss, Tops Revenue Estimates
Invitae (NVTA) delivered earnings and revenue surprises of -32.69% and 2.75%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Invitae Reports $56.5 Million in Quarterly Revenue Driven by 129,000 Samples
-- Increased quarterly revenue by 51% and volume by 65% year-over-year -- -- Now in network with Cigna, all major payers with approximately 295 million covered lives -- -- Hosting conference call and webcast ...
- PR Newswire
Invitae Highlights Importance of Medical Genetics, Honors Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC) 38th Annual Conference
SALT LAKE CITY , Nov. 5, 2019 /PRNewswire/ -- Researchers from Invitae Corporation (NYSE: NVTA), a leading medical genetics company, are presenting research this week at the National Society of Genetic ...
- Zacks
Will Genetic Testing Drive Invitae's (NVTA) Q3 Earnings?
Several bio-pharma partnerships and acquisitions are likely to have contributed to Invitae's (NVTA) top line in Q3.
- Investopedia
8 Undervalued Biotech Stocks to Watch Now
As investors shift out of growth names and to more defensive pockets of the market, market watchers now see these biotech players as undervalued.
- Zacks
Earnings Preview: Invitae (NVTA) Q3 Earnings Expected to Decline
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Is InVitae Corporation (NVTA) A Good Stock To Buy?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
- PR Newswire
Invitae to announce third quarter 2019 financial results on November 6, 2019
SAN FRANCISCO, Oct. 23, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced that it will report its third quarter 2019 financial results on Wednesday, November 6, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 9085356.
- Benzinga
InVitae Shares Bounce Back Following Analyst Rebuttal To Short Seller Allegations
On Oct. 11, a short seller article published on Seeking Alpha accused InVitae of being the next Theranos. The short seller implied InVitae’s strong revenue growth may have been obtained via fraudulent measures and InVitae is burning through cash at an irresponsible level. On Oct. 13, Capital Markets Laboratories CEO Ophir Gottlieb published a rebuttal to the Seeking Alpha story.
- PR Newswire
Research presented by Invitae at the American Society of Human Genetics Meeting Pushes Science and Practice of Genetics Forward
-- Advances in classification, new approaches to genetics in cancer and implications of primary and secondary findings for clinical care among wide-ranging data presentations -- HOUSTON , Oct. 17, 2019 ...
